Fluvoxamine, one of the oldest selective serotonin reuptaking inhibitors, is commonly prescribed to patients with major depression. Several studies have reviewed the efficacy and tolerability of fluvoxamine for the treatment of major depression. However, these reviews are outdated, have not been systematic and/or suffered from several methodological weaknesses. We conducted a systematic review to synthesize the best available evidence on the efficacy of fluvoxamine for adult patients suffering from major depression in comparison with other active antidepressive agents. Relevant randomized controlled trials were identified through a comprehensive search. The primary outcome was a relative risk of response, and the secondary outcome was a relative risk of remission. Tolerability and side-effect profile were also examined. Fifty-three trials were included. There were no large differences between fluvoxamine and any other antidepressants in terms of efficacy and tolerability. There is evidence of differing side effect profiles, especially when comparing gastrointestinal side effects between fluvoxamine and tricyclics. Clinicians should focus on practically or clinically relevant differences including those in side-effect profiles.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, fourth ed.Washington, DC : American Psychiatric Press .
2.
American Psychiatric Association (2000) Practice guideline for the tratment of patients with major depressive disorder.Am J Psychiatry157: 1 – 45 [revision].
3.
Anderson IM (1998) SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability.Depress Anxiety7(Suppl. 1): 11 – 17 .
4.
Anderson IM Edwards JG (2001) Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness.Adv Psychiatric Treat7: 170 – 180 .
5.
Anderson IM Nutt DJ Deakin JF (2000) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology.J Psychopharmacol14: 3 – 20 .
6.
Arroll B Macgillivray S Ogston S Reid I Sullivan F Williams B (2005) Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis.Ann Fam Med3: 449 – 456 .
7.
Barbui C Cipriani A Brambilla P Hotopf M (2004) " Wish bias" in antidepressant drug trials?J Clin Psychopharmacol24: 126 – 130 .
8.
Barbui C Furukawa TA Cipriani A (2008) Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials.Can Med Assoc J178: 296 – 305 .
9.
Barbui C Hotopf M Freemantle N Boynton J Churchill R Eccles MP (2000) Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence.Cochrane Database Syst Rev: CD002791 .
10.
Buchkowsky SS Jewesson PJ (2004) Industry sponsorship and authorship of clinical trials over 20 years.Ann Pharmacother38: 579 – 585 .
11.
Burton SW (1991) A review of fluvoxamine and its uses in depression.Int Clin Psychopharmacol6(Suppl. 3): 1 – 17 , discussion 17–21.
12.
Cipriani A Barbui C Brambilla P Furukawa TA Hotopf M Geddes JR (2006) Are all antidepressants really the same? The case of fluoxetine: a systematic review.J Clin Psychiatry67: 850 – 864 .
13.
Ciuna A Andretta M Corbari L Levi D Mirandola M Sorio A (2004) Are we going to increase the use of antidepressants up to that of benzodiazepines?.Eur J Clin Pharmacol60: 629 – 634 .
14.
Claassen V Davies JE Hertting G Placheta P (1977) Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor.Br J Pharmacol60: 505 – 516 .
15.
Edwards JG Anderson I (1999) Systematic review and guide to selection of selective serotonin reuptake inhibitors.Drugs57: 507 – 533 .
16.
Egger M Davey Smith G Schneider M Minder C (1997) Bias in meta-analysis detected by a simple, graphical test.BMJ315: 629 – 634 .
17.
Ellis P (2004) Australian and New Zealand clinical practice guidelines for the treatment of depression.Aust N Z J Psychiatry38: 389 – 407 .
18.
Fuller RW Wong DT (1987) Serotonin reuptake blockers in vitro and in vivo.J Clin Psychopharmacol7: 36S – 43S .
19.
Furukawa TA Akechi T Azuma H Okuyama T Higuchi T (2007a) Evidence-Based Guidelines for Interpretation of the Hamilton Rating Scale for Depression.J Clin Psychopharmacol27: 531 – 534 .
20.
Furukawa TA Barbui C Cipriani A Brambilla P Watanabe N (2006) Imputing missing standard deviations in meta-analyses can provide accurate results.J Clin Epidemiol59: 7 – 10 .
21.
Furukawa TA Cipriani A Barbui C Brambilla P Watanabe N (2005) Imputing response rates from means and standard deviations in meta-analysis.Int Clin Psychopharmacol20: 49 – 52 .
22.
Furukawa TA Guyatt GH Griffith LE (2002) Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses.Int J Epidemiol31: 72 – 76 .
23.
Furukawa TA Watanabe N Omori IM Montori VM Guyatt GH (2007b) Association between unreported outcomes and effect size estimates in Cochrane meta-analyses.JAMA297: 468 – 470 .
24.
25.
Geddes JR Freemantle N Mason J Eccles MP Boynton J (2000) Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depressive disorder.Cochrane Database Syst Rev: CD001851 .
26.
Greenberg PE Birnbaum HG (2005) The economic burden of depression in the US: societal and patient perspectives.Expert Opin Pharmacother6: 369 – 376 .
27.
Greenberg PE Kessler RC Birnbaum HG Leong SA Lowe SW Berglund PA (2003) The economic burden of depression in the United States: how did it change between 1990 and 2000?J Clin Psychiatry64: 1465 – 1475 .
28.
Guaiana G Andretta M Corbari L Mirandola M Sorio A D'Avanzo B (2005) Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000.J Clin Psychiatry66: 750 – 755 .
29.
Guaiana G Barbui C Hotopf M (2003) Amitriptyline versus other types of pharmacotherapy for depression.Cochrane Database Syst Rev: CD004186 .
30.
Hamilton M (1960) A rating scale for depression.J Neurol Neurosurg Psychiatry23: 56 – 62 .
31.
Hammad TA Laughren T Racoosin J (2006) Suicidality in pediatric patients treated with antidepressant drugs.Arch Gen Psychiatry63: 332 – 339 .
32.
Hansen RA Gartlehner G Lohr KN Gaynes BN Carey TS (2005) Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder.Ann Intern Med143: 415 – 426 .
33.
Harris B Szulecka TK Anstee JA (1991) Fluvoxamine versus amitriptyline in depressed hospital out-patients: a multicentre double-blind comparative trial.British Journal of Clinical Research2: 89 – 99 .
34.
JP Higgins S Green (eds) (2005) Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. Chichester : John Wiley & Sons Ltd.
35.
Kadusevicius E Mikucionyte L Maciulaitis R Milvidaite I Sveikata A (2006) Trends in the consumption of antidepressant drugs in Lithuania in 2002–2004.Medicina (Kaunas)42: 1020 – 1029 .
36.
Kavoussi RJ Hauger RL Coccaro EF (1999) Prolactin response to d-fenfluramine in major depression before and after treatment with serotonin reuptake inhibitors.Biol Psychiatry45: 295 – 299 .
37.
Kostiukova EG Granenov GM Andreichik LA Serditov OV Mosolov SN (2003) Comparative efficacy and tolerance of fluvoxamine and amitriptyline in the treatment of moderate and severe depression in mental hospital.Zh Nevrol Psikhiatr Im S S Korsakova103: 24 – 29 .
38.
Lawrenson RA Tyrer F Newson RB Farmer RD (2000) The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared.J Affect Disord59: 149 – 157 .
39.
Mackay FJ Dunn NR Wilton LV (1997) A comparison if fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies.Pharmacoepidemiol Drug Saf6: 235 – 246 .
40.
Montejo-Gonzalez AL Llorca G Izquierdo JA (1997) SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients.J Sex Marital Ther23: 176 – 194 .
41.
Montgomery SA Asberg M (1979) A new depression scale designed to be sensitive to change.Br J Psychiatry134: 382 – 389 .
42.
Mottram P Wilson K Strobl J (2006) Antidepressants for depressed elderly.Cochrane Database Syst Rev: CD003491 .
43.
NICE (2004) Depression: Management of Depression in Primary and Secondary Care.London : National Institute for Clinical Excellence .
44.
Perlis RH Perlis CS Wu Y Hwang C Joseph M Nierenberg AA (2005) Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry.Am J Psychiatry162: 1957 – 1960 .
45.
Puech A Montgomery SA Prost JF Solles A Briley M (1997) Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.Int Clin Psychopharmacol12: 99 – 108 .
46.
Remick RA Reesal R Oakander M Allen J Claman J Ramirez CE (1994) Comparison of fluvoxamine and amitriptyline in depressed outpatients.Curr Ther Res Clin Exp55: 243 – 250 .
47.
Smith D Dempster C Glanville J Freemantle N Anderson I (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.Br J Psychiatry180: 396 – 404 .
48.
Taylor MJ Freemantle N Geddes JR Bhagwagar Z (2006) Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis.Arch Gen Psychiatry63: 1217 – 1223 .
49.
The Nordic Cochrane Centre (2003) Review Manager (RevMan) [Computer program]. Version 4.2 for Windows. Copenhagen: The Cochrane Collaboration.
50.
US Department of Heath and Human Services : Agency for Health Care Policy and Research (1993) Depression Guideline Panel. Clinical Practice Guideline: Depression in Primary Care 2: Treatment of Major Depression. Vol. Rockville, MD: AHCPR Publication 93-0551.
51.
Ware MR (1997) Fluvoxamine: a review of the controlled trials in depression.J Clin Psychiatry58(Suppl. 5): 15 – 23 .
52.
Watanabe N; Omori IM; Nakagawa A; Cipriani A; Barbui C; McGuire H; (in press) Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: Systematic review and meta-analysis. J Clin Psychiatry.
53.
54.
Williams JW Mulrow CD Chiquette E Noel PH Aguilar C Cornell J (2000) A systematic review of newer pharmacotherapies for depression in adults: evidence report summary.Ann Intern Med132: 743 – 756 .
